Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab, Bevacizumab, and Tocilizumab in Advanced Hepatocellular Carcinoma
NCT07774247Phase 2Not yet recruiting
- Sponsor
- CHA University
- Start
- Sep 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tocilizumab in hepatocellular carcinoma (HCC), sponsored by CHA University. Primary endpoint: Incidence of Grade >=3 Immune-Related Adverse Events at 24 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
tocilizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07774247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07774247.